Background/Aims: microRNA (miR)-374a plays a crucial role in cancer progression by promoting the metastasis and proliferation of various types of malignant tumors. Because its role in bladder cancer is unknown, we investigated whether miR-374a affects the progression of bladder cancer and studied the underlying mechanism. Methods: The Cancer Genome Atlas was used to analyze the clinical relevance of miR-374a. Quantitative PCR, western blotting, and luciferase and immunofluorescence assays were used to detect the expression patterns, downstream targets, and function of miR-374a in bladder cancer cells. Apoptosis was evaluated by flow cytometry after cisplatin treatment. Results: Via in silico analysis, low levels of miR-374a were associated with poor prognosis in bladder cancer patients with distant metastasis. WNT5A was a direct target of miR-374a in two bladder cancer cell lines. miR-374a mimic abrogated the metastatic potential and invasiveness of bladder cancer cells via WNT5A downregulation in both T24 and TCCSUP human bladder cancer cells; the opposite was observed with miR-374a inhibitor. In addition, miR-374a treatment reduced the phosphorylation and nuclear translocation of β-catenin. Cisplatin treatment significantly increased the apoptosis rate. Expression levels of cancer stemness-related proteins were reduced in miR-374a mimic-pretreated cells. Conclusion: Lower expression of miR-374a is associated with poor prognosis and miR-374a improves tumor biological behavior in bladder cancer cells, suggesting that miR-374a might be a novel small-molecule therapeutic target.
Transfection
Invitrogen was authorized to construct the adenoviruses encoding human-WNT5A (Ad-WNT5A) and GFP (Ad-GFP, negative control). When T24 cells reached 80% confluence, they were infected with Ad-WNT5A or control viruses using Lipofectamine 2000 (Invitrogen) according to the manufacturer's standard protocol, incubated for 24 h, and then treated with the miR-374a mimic for 12 h. The cells were subsequently collected and lysed for various assays.
RNA extraction and quantitative PCR
After treatment with the miR-374a mimic, inhibitor, or scrambled control, total RNA was isolated from human urethral epithelial cells (HUEpCs) and bladder cancer cells using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. The total RNA was reverse transcribed using hexamer primers and Superscript III reverse transcriptase (Invitrogen) for analysis of transcript levels. Subsequently, quantitative polymerase chain reaction (qPCR) was performed using the SYBR Green PCR Master Mix. miRNA transcriptional analysis was performed after reverse transcription, followed by qPCR, as described before [22] . qPCR for miRNAs was performed with the miScript SYBR Green PCR kit (Qiagen, Shanghai, China). GAPDH mRNA and U6 small RNA were used as endogenous controls for mRNA and miRNA expression, respectively. The relative expression level was calculated using the 2 −ΔΔCt method. The sequences of the upstream and downstream primers were as follows: WNT5A: F-5′ACACGATGGT CAAAGCTAGT CGTAG-3′, R-5′ACGGTCAGTT GTTCAGTTCC-3′; GAPDH: F-5′CAAGGTCATC CATGACAACTT TG-3′, R-5′GTCCACCACC CTGTTGCTGT AG-3′; U6: F-5′CTCGCTTCGG CAGCACA-3′, R-5′AACGCTTCAC GAATTTGCGT-3′.
Western blotting
Western blotting was performed using the following primary antibodies: WNT5A (ab72583, 1:2000), β-catenin (ab32572, 1:10000), phosphorylated β-catenin (ab27798, 1:1000), ABCG2 (ab24115, 1:100), CD133 (ab19898, 1:1000), and SOX2 (ab92494, 1:2000) . All primary antibodies were purchased from Abcam Plc. (Cambridge, UK). Cells were lysed with lysis buffer for 10 min and then centrifuged at 12, 000 × g for 10 min at 4°C. The concentration of the protein lysates was estimated using BioTek EPOCH (Winooski, VT, USA). Protein samples were heat-denatured at 100°C for 5 min. Equivalent protein lysates were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. The membranes were first blocked with 5% (w/v) dried skim milk in Tris-buffered saline with Tween 20 (TBST) for 1 h at 25°C and then probed with the indicated primary antibodies overnight at 4°C. Next, the membranes were washed thrice with 1× TBST and incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies for 2 h at room temperature. β-actin (anti-β-actin from Kangcheng, Inc., Shanghai, China) was used as an internal control. After three washes with TBST, the proteins were detected using an enhanced chemiluminescence system (Pierce Biotechnology, Rockford, IL, USA) and Alpha Innotech Fluorchem SP (San Leandro, CA, USA).
Wound-healing assay
A wound-healing assay was performed to evaluate cell migration. Cells were seeded on 6-well plates in RPMI-1640 medium containing 10% FBS. After 24 h, straight lines were drawn by scraping the confluent cells with a 20-µL pipette tip and ruler. Subsequently, the medium and floating cells were carefully removed and the adherent cells were washed thrice with PBS and cultured in serum-free medium. After 16 h of incubation, the wound-healing process was monitored under a phase contrast microscope. The migration distance was measured using representative images obtained at 0 and 16 h.
Cell migration and invasion assays
Transwell assays were performed to assess cell invasion using the HTS Transwell-24 system (Corning Inc., Corning, NY, USA). Cells were cultured in serum-free RPMI-1640 medium for 24 h. Then, 100 µL of 5 × 10 4 cells were seeded onto the upper chamber, and the lower chamber was filled with 600 µL of RPMI-1640 medium supplemented with 10% FBS as a chemoattractant. The cells in the upper chamber (without serum) have a tendency to pass through the membrane to the culture medium containing 10% FBS in the lower compartment, allowing an estimation of migratory and invasive abilities. After incubation at 37°C for 24 h, the cells that passed through the membrane and were in the lower compartment were stained with 0.2% crystal violet, fixed with 30% glycerin on the slides, and then counted under a light microscope. Immunofluorescence Cells were adhered on coverslips in 6-well plates, and after 24 h in culture, were fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.2% Triton X-100 for 15 min, and blocked with phosphate buffer containing 3% bovine serum albumin for 30 min at room temperature. After incubation with rabbit anti-β-catenin (Abcam) overnight at 4°C, the coverslips were incubated with CY3-conjugated goat antirabbit IgG secondary antibodies for 30 min and treated with 4',6-diamidino-2-phenylindole (DAPI) (SigmaAldrich, St. Louis, MO, USA) for nuclear staining. The cells were examined using confocal laser scanning microscopy (Leica, Wetzlar, Germany).
Cell viability assay and chemotherapeutic drug treatment
Cell viability was evaluated using flow cytometry according to standard protocols. In total, 10 4 cells were treated with the miR-374a mimic or control oligonucleotides and seeded in 96-well plates, and CDDP (1 μmol/L, Sigma) was added for 2-4 days. Cells were harvested and washed with PBS 48 h after transfection. Cells (~0.5 × 10 6 ) were resuspended in the flow cytometry staining buffer (eBioscience, Frankfurt, Germany) and stained with annexin V-FITC/propidium iodide (PI) (eBioscience) in the dark for 30 min. Cell apoptosis was detected by flow cytometry according to the annexin V-FITC/PI kit protocol and detected using CellQuest Pro software (BD Biosciences, San Jose, CA, US). The flow cytometry data were analyzed using FlowJo 6.0 (BD Biosciences).
TCGA database
We used the public website PROmiR2 (http://xvm145.jefferson.edu/progmir/index.php) to determine whether miR-374a exerted any positive influence on the prognosis of patients with bladder cancer. The raw data are freely available on the website of TCGA database. The website directly offers the survival curve and statistical results according to the survival data. We downloaded the survival data and analyzed the corresponding figures using the Kaplan-Meier method, followed by a log-rank test.
Statistical analysis
Each experiment was repeated at least three times and the data are presented as the mean ± standard error of the mean (SEM). Unpaired t-tests were used to determine the statistical differences between two groups in each analysis. P < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS 13.0 software (SPSS Inc., Chicago, IL, USA).
Results

Analysis of TCGA database
We performed survival analysis using TCGA database to determine whether miR-374 can be used to predict clinical prognosis. First, we categorized patients with bladder cancer into two groups according to miR-374a level (high or low) based on the recommended standard on the PROGmiR2 website (http://xvm145.jefferson.edu/progmir/index.php) [23] . Next, we analyzed the survival data in different subgroups based on the extent of metastasis. We observed that poor overall survival (OS) in patients with lower levels of miR-374a in the subgroup with metastasis (odds ratio [OR] = 0.6, 95% confidence interval [CI]: 0.39-0.93, P = 0.02), and a difference was observed in relapse-free survival (RFS) between the two subgroups (P = 0.68) ( Fig. 1A and 1B ). In the non-metastasis subgroup, poor RFS was seen in the subgroup with lower levels of miR-374a (OR = 0.35, 95% CI: 0.21-0.6, P < 0.01), although the OR of the two subgroups was similar ( Fig. 1C and 1D ). In the combined patient group, neither OS nor RFS differed between the subgroups ( Fig. 1E and 1F) , which demonstrated that metastasis should be considered in survival analysis because of the poor prognosis of patients with distant metastasis.
miR-374a directly targets WNT5A bladder cancer cells
We measured the miR-374a transcript levels in normal HUEpCs and bladder cancer cells by qPCR to determine whether miR-374a transcription was reduced in cancer cells.
Unexpectedly, the miR-374a transcript level was similar in HTB-9 cells and HUEpCs, but the transcript levels were significantly lower in T24 and TCCSUP cells than in HUEpCs ( Fig. 2A) . These results indicate the heterogeneity of miR-374a transcription among various bladder cancer cell lines, which is reminiscent of the differential transcription levels observed in clinical samples. Additionally, we observed high metastatic activity in T24 cells compared with HTB-9 cells (data not shown). Therefore, we selected the T24 and TCCSUP cells to further investigate the role of miR-374a in bladder cancer.
We used western blot to detect the expression of the potential targets of miR-374a, such as PTEN, WIF1, and WNT5A. PTEN expression was low in T24 cells but not in TCCSUP cells, whereas WNT5A was highly expressed in both cell lines (Fig. 2B) . We hypothesized that miR374a did not influence PTEN and WIF1 expression in bladder cancer cells. To further validate this theory, we performed qPCR in T24 and TCCSUP cells after treatment with a miR-374a mimic. As expected, the miR-374a mimic decreased the expression of WNT5A alone and not PTEN and WIF1 ( Fig. 2C and 2D ). Thus, unlike in breast cancer cells, the miR-374a mimic targeted WNT5A for downregulation in bladder cancer cells, without affecting PTEN and WIF1 expression. Furthermore, a dual-luciferase reporter system with vectors comprising the mutant or wild-type WNT5A 3'-UTR were used to confirm if WNT5A is a direct target of miR-374a (Fig. 2E ). We observed decreased relative wild-type WNT5A 3'-UTR luciferase activities in both T24 and TCCSUP cells lines. However, the mutant luciferase activities were unchanged after miR-374a mimic treatment ( Fig. 2F and 2G ). These results suggested that WNT5A is a direct target of miR-374a.
miR-374a suppresses the metastatic potential and invasiveness of bladder cancer cells via WNT5A downregulation
As shown in Fig. 3A , WNT5A transcript was greatly upregulated after introduction of an adenovirus vector overexpressing WNT5A into T24 cells. Functionally, overexpression of WNT5A aggravated the metastasis and invasiveness of T24 cells in wound-healing and Transwell assays (Fig. 3B-D) . In addition, treatment with the miR-374a mimic significantly abrogated the metastatic ability and invasiveness of T24 cells (Fig. 3B-D) . Thus, both miR-374 and WNT5A can alter bladder cell biology. 
Cellular Physiology
To determine whether the effect of miR-374a on cancer cell biology was via WNT5A downregulation, T24 cells overexpressing WNT5A were treated with miR-374a mimic. First, we observed that miR-374a mimic significantly abrogated the increase in WNT5A (Fig.  3B-D) . Second, the increased metastasis and invasiveness of T24 cells induced by WNT5A overexpression were also suppressed (Fig. 3B-D) . Similar results were observed in TCCSUP cells (Fig. 3E-H) .
In addition, treatment of T24 and TCCSUP cells with miR-374a inhibitor significantly increased the metastatic ability and invasiveness of T24 cells, which were accompanied by increased WNT5A transcript (Fig. 4) . Taken together, these data suggested that miR-374a inhibited metastasis and invasiveness in vitro via WNT5A downregulation.
miR-374a-induced downregulation of WNT5A inhibits the canonical Wnt/β-catenin signaling pathway
We further investigated whether regulation of miR-374a and WNT5A levels was associated with Wnt noncanonical signaling. Previous work showed that WNT5A, a noncanonical ligand of the Wnt family, plays opposing roles in cancer biology [24] . However, one recent study showed that WNT5A activates phosphokinase A to deactivate GSK3b and stabilize b-catenin, which in turn activates the canonical Wnt signaling pathway [25] . We measured the phosphorylation and protein levels of b-catenin after introduction of the WNT5A-overexpressing adenovirus vector. The results revealed decreased phosphorylation but similar protein levels of b-catenin, which showed that WNT5A treatment did not influence b-catenin transcription (Fig. 5A) . Moreover, phosphorylation of GSK3b was increased, which suggested GSK3b inactivation [26] .
Next, we performed western blotting and immunofluorescence assays to measure the activation of the Wnt signaling pathway after introduction of miR-374a. We observed 
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Cellular Physiology and Biochemistry increased nuclear translocation and reduced phosphorylation of β-catenin after introduction of the miR-374a mimic into T24 cells ( Fig. 5B and 5C ). Introduction of miR-374a into T24 cells increased the phosphorylation levels of b-catenin and reduced its nuclear translocation, which suggested that miR374a could inhibit the canonical Wnt signaling pathway (Fig. 5C) . Moreover, overexpression of WNT5A reversed the inhibition of Wnt/b-catenin signaling observed after treatment with the miR374a mimic, which demonstrated that WNT5A activated the canonical Wnt/β-catenin signaling pathway in bladder cancer cells ( Fig. 5B and 5C ). Overall, our data showed that the noncanonical ligand WNT5A activated the tumor-promoting canonical Wnt signaling pathway in the same way as observed in human dermal fibroblasts [27] . Then, we used CP21, a highly selective inhibitor of GSK3β, to activate Wnt signaling and investigate its effect on the metastatic and invasive abilities of the T24 cell line after treatment with the miR-374a mimic. CP21 partially restored metastatic ability and invasiveness on Transwell and wound-healing assays after treatment with miR-374a ( Fig. 5D  and 5E ). These results indicated that miR374a-induced downregulation of WNT5A inhibited the canonical Wnt/b-catenin signaling pathway.
miR-374a mimic reduces cancer stemness and increases sensitivity to cisplatin
We investigated whether the miR374a mimic could alter cancer stemness and sensitivity to chemotherapeutic drugs in bladder cancer cell lines via inhibition of the Wnt signaling pathway. Introduction of the miR-374a mimic blocked the Wnt signaling pathway, which has multiple effects on tumor biology, including metastasis, cell proliferation, cancer cell stemness, and neovascularization in the carcinoma microenvironment [28, 29] . We speculated that the miR-374a treatment negatively regulated not only metastasis and invasion, but also other biological mechanisms associated with poor prognosis because we observed poor prognosis in patients with lower miR-374a levels in the distant metastasis subgroups from the survival data. Hence, we considered increased chemotherapeutic sensitivity to be another possible phenotypic conversion mechanism after blockade of Wnt signaling in bladder cancer cell lines. We measured the apoptosis rate and sensitivity to cisplatin by flow cytometry and found that pretreatment with the miR-374a mimic significantly promoted apoptosis of bladder Cell (Fig. 6A and 6B ). Furthermore, we observed reduced expression of gene markers related to cancer cell stemness, including SOX2, CD133, and ABCG2, indicating that miR-374a deficiency might be involved in the chemotherapeutic resistance via enhancement of cancer cell stemness ( Fig. 6C and 6D ). These observations illustrated that the miR-374a mimic could block the Wnt/β-catenin signaling pathway to regulate different tumor behaviors, including metastasis, invasion, cancer stemness, apoptosis, and drug resistance.
Discussion
Although numerous studies have demonstrated the effects of transcriptional deregulation in bladder cancer, including the overexpression or deficiency of miRNAs and abnormal methylation levels of target genes, further in-depth investigation of the mechanisms underlying abnormal transcriptional regulation was warranted by the identification of personalized transcriptional deregulation in various types of cancer and the complicated functions of miRNAs [8, 16] . Dysregulation of miRNA expression varies among different types of cancer. Yoshino et al [30] . found that miR-99, miR-100, miR-101, and miR-145 were downregulated in NMIBC but not in MIBC using miRNA microarray. miRNA dysfunction is also dependent on the pathological grade of bladder cancer. High-grade bladder carcinomas (MIBC or NMIBC) share an aberrant miRNA transcription profile, which is distinct from that of their low-grade counterparts. This similarity in the miRNA profile assists clinicians in determining the therapy required for patients with high-grade NMIBC. However, because abnormal gene expression varies with the pathological grade and clinical type of tumor, the intervention strategy for tumors with different biological features would also vary.
In this study, we observed that the transcript levels of miR-374a were positively correlated with disease prognosis. Therefore, we hypothesized that miR-374a might act as an anti-tumor small non-coding RNA. After adjustment for metastatic status, patients with high levels of miR-374a have longer survival and RFS times. NMIBC patients with high levels of miR-374a have a longer RFS, which suggests that miR-374a inhibits tumor metastasis and aggressive biological behavior. A previous study showed that miR-374a promoted the epithelial-mesenchymal transition in breast cancer via activation of the canonical Wnt signaling pathway, which aggravates metastasis and invasion in vitro [16] . These observations contrast with our results on the role of miR-374 in bladder cancer and its effect on disease prognosis. Previous study demonstrated that WNT5A, a noncanonical Wnt ligand, plays a vital tumor-promoting role in bladder cancer [20] . Other studies of the role of WNT5A in tumor malignancy reported inconsistent results. For example, Topol et al [31] . showed that [32] . found that WNT5A plays a tumor-promoting role in various cancers via an unrecognized noncanonical Wnt pathway. Binding of WNT5A to the Fzd2 receptor activates STAT3 and promotes the Janus kinase-independent epithelialmesenchymal transition. In contrast, Mikels and Nusse [33] observed that WNT5A also activated b-catenin transcription via its specific receptor (overexpressed Fz-4 and LRP5), but did not affect b-catenin phosphorylation and stability.
Nonetheless, recent studies have demonstrated that WNT5 can activate PKA and in turn inactivate GSK3b, which leads to stabilization and enhanced nuclear translocation of b-catenin [25] . Additionally, they showed that the noncanonical Wnt ligand WNT5A can activate the canonical Wnt signaling pathway via inactivation of GSK3b in human dermal fibroblasts. Our results are consistent with the findings of the above study. We found that WNT5A aggravates bladder cancer via activation of the canonical Wnt signaling pathway. After considering the varying results obtained with other malignant tumors, we hypothesized that the distinct biological effects observed in different cell lines could be attributed to differences in the isoforms of the WNT5A receptors belonging to the Frizzled receptor family. In other words, the signaling pathway activated after WNT5A treatment depends on the isoform of the Frizzled receptor present in the cell type. This hypothesis might explain the contradictory results observed with WNT5A signaling in breast and bladder cancer cells.
Reports show that WNT5A has contradictory effects on tumorigenicity [16, 18, 20] . We observed that WNT5A treatment aggravated bladder cancer metastasis and invasiveness with increased phosphorylation of b-catenin. The role of WNT5A in bladder cancer is still ambiguous because of the opposing results reported in previous studies. Some groups found that WNT5A levels were positively correlated with the histological grade and clinical stage of bladder cancer and that the WNT5A mRNA levels varied widely among different cell lines [25] . Furthermore, aberrant expression of CDC42BPB, WNT5A, and ROBO1 could be used for the molecular diagnosis of bladder cancer [34] . Our study demonstrated that WNT5A may act as a potential biomarker and tumor-promoting factor in bladder cancer. We found that WNT5A activated the canonical Wnt signaling pathway and promoted cell invasion and metastasis, which worsened the tumor phenotype. The activation of the canonical Wnt signaling pathway also resulted in other phenotypic changes, including apoptosis, chemotherapy resistance, and cancer stemness [28] . Therefore, we performed flow cytometry to assess the apoptosis rate after treatment with cisplatin and evaluated the levels of proteins related to cancer stemness. We observed that inactivation of the canonical Wnt signaling pathway via WNT5A downregulation not only attenuated metastasis and invasion, but also reduced cancer stemness and enhanced sensitivity to cisplatin. Overall, these results demonstrated that miR-374a exerts anti-tumor effects via downregulation of WNT5A and blockade of the canonical Wnt signaling pathway in bladder cancer.
In conclusion, miR-374a exerts an anti-tumor effect in bladder cancer. miR-374a specifically targets WNT5A, a noncanonical Wnt ligand that activates canonical Wnt signaling in the presence of specific receptors in bladder cancer cells, abrogates the invasiveness and metastasis potential, and increases apoptosis after cisplatin treatment. Therefore, miR-374a may be a novel therapeutic target in bladder cancer patients with low levels of miR-374a transcripts.
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